Johnson & Johnson became the latest company to have a failed vaccine trial against HIV last week. While it was a great disappointment to many, efforts continue in this space, helped by recent Covid-19 vaccine advances.
HIV has been around for decades. While antiretroviral treatments have improved enormously, turning what was once a death sentence into a chronic condition, an effective prophylactic vaccine has proved elusive.
One reason it’s so difficult to develop a vaccine for HIV is that the virus mutates very quickly.
“HIV has a tremendous amount of variability,” said Kimberly Smith, Head of R&D at the UK company ViiV Healthcare, which develops treatments for HIV infections. “When we talk about the coronavirus that’s the cause of Covid-19, we talk about the various variants, which right now are just a handful. But HIV is literally hundreds, perhaps thousands of times more variable than the coronavirus.”
Another challenge facing vaccine makers is that HIV can escape immune detection.
The post As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.